Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 6/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264455 | 0.88 | PDE3B (0.45) | PDE3BPDE3AAMY1ABRD4PDGFRB | |
| SCHEMBL5261238 | 0.78 | PDE3B (0.40) | PDE3BPDE3AAMY1ACYP19A1NQO2 | |
| SCHEMBL14463229 | 0.75 | ACVR1 (0.41) | POLB | |
| SCHEMBL29533227 | 0.74 | KDM4E (0.56) | PDE3BPDE3APOLBKMT2A | |
| SCHEMBL3319211 | 0.74 | KDM4E (0.56) | PDE3BPDE3APOLBKMT2A | |
| SCHEMBL14367995 | 0.73 | SMN1; SMN2 (0.42) | PDE3BPDE3AAMY1ASLC10A2 | |
| SCHEMBL4980044 | 0.72 | PDE5A (0.45) | PDE3BPDE3ACYP19A1NQO2PDGFRB | |
| SCHEMBL8808049 | 0.70 | ALDH1A1 (0.54) | PDE3BPDE3ABRD4CYP19A1NQO2 | |
| SCHEMBL1191538 | 0.70 | AMY1A (0.46) | PDE3BPDE3AAMY1ANQO2KMT2A | |
| SCHEMBL5264451 | 0.69 | GRIN2D (0.43) | PDE3BPDE3ACYP19A1NQO2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
| CN-1845908-A | 5-substituted quinazolinone derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-11 | — | — | CN | disclosed |
| CN-1845924-A | Arylamine-substituted quinazolinone compounds | HOFFMANN LA ROCHE (CH) | 2006-10-11 | — | — | CN | disclosed |
| EP-1644343-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| EP-1644369-A2 | ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005005395-A2 | ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005397-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | PDE3B 381/4885PDE3A 390/4885AMY1A 388/4885 |
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1B, ADRB2 | PDE3B 598/4885PDE3A 860/4885AMY1A 846/4885 |
| US-20050038016-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | PDE3B 381/4885PDE3A 390/4885AMY1A 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.